Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued to investors on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their price objective on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, August 23rd.

Evogene Price Performance

EVGN opened at $1.46 on Wednesday. Evogene has a fifty-two week low of $1.44 and a fifty-two week high of $10.40. The firm has a market capitalization of $7.84 million, a PE ratio of -0.33 and a beta of 1.36. The company’s 50-day moving average is $2.19 and its 200 day moving average is $4.13.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGN) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.